Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

PTC-596 shows efficacy in a number of tumor models in vivo

Nov. 16, 2012

Phase I trial of IMO-8400 begins, preclinical results presented

Nov. 16, 2012

Brodalumab does not demonstrate meaningful clinical efficacy in patients with RA

Nov. 15, 2012

Safety results presented from the AMETHYST-DN study

Nov. 15, 2012

MRC reports results of heterologus prime vaccination study at the ASTMH meeting in Atlanta

Nov. 14, 2012

Phase I results presented for the FMP-012 malaria vaccine

Nov. 14, 2012

Novel dual NADPH oxidase inhibitor shows excellent safety/pharmacokinetic profile

Nov. 14, 2012

sGPVI as a risk marker in inflammatory arthritis

Nov. 14, 2012

Preliminary clinical results presented for FG-4592 in hemodialysis patients

Nov. 14, 2012

Interim results presented for a peptide-based cancer vaccine

Nov. 13, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...